Gastrointestinal Disease Clinical Trial
— MDEBMICOfficial title:
Cutaneous Adverse Effects Occurring in Children Under Biological Therapy Given for Chronic Inflammatory Diseases
Verified date | July 2021 |
Source | Centre Hospitalier Universitaire, Amiens |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Biological treatments (BT) are commonly prescribed to treat chronic inflammatory diseases in children. Paradoxical reactions during treatment with a biological agent can be defined as the appearance or exacerbation of a pathological condition that usually responds to this class of drug while treating a patient for another condition. Limited data are available in children treated by BT on cutaneous paradoxical reactions, or any other cutaneous adverse events occurring during treatment. On the contrary, dermatologists tend to see and manage increasing numbers of cutaneous adverse events, including paradoxical reactions. The aim of this project is to describe the incidence of cutaneous adverse events, including cutaneous paradoxical reactions, occurring in the pediatric population, during a treatment by BT given for a chronic inflammatory disease.
Status | Completed |
Enrollment | 20 |
Est. completion date | October 1, 2020 |
Est. primary completion date | July 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 18 Years |
Eligibility | Inclusion Criteria: - Children under 18 years old - Children treated by biotherapy among : Adalimumab, Golimumab, Infliximab, Ustekinumab, Etanercept, Tocilizumab, Canakinumab, Anakinra, Abatacept. - Children treated for a chronic inflammatory disease (rheumatologic, gastro-enterologic, dermatologic and ophthalmologic) - Children treated in the CHU of Amiens - Parental consent signed Exclusion Criteria: - Age > 18 ans |
Country | Name | City | State |
---|---|---|---|
France | CHU Amiens | Amiens |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire, Amiens |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Variation of the incidence of cutaneous adverse events under biological therapy | Determine the variation of the incidence of any skin manifestation under biological therapy, including Paradoxical Reaction (psoriasis, eczema, hidradenitis suppurativa …), non-paradoxical inflammatory reaction, infection, neoplasia, hair and nail manifestation, xerosis. | up to 8 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03566160 -
Pilot Study for Evaluation of Cryobiopsy and Correlation With Standard Forceps Biopsy
|
N/A | |
Active, not recruiting |
NCT05053191 -
Advancing Nursing Practices in Hospital Oncology Care
|
N/A | |
Recruiting |
NCT03602677 -
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
|
N/A | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Completed |
NCT00671177 -
Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique
|
N/A | |
Completed |
NCT00910104 -
Cholestasis Reversal: Efficacy of IV Fish Oil
|
Phase 2/Phase 3 | |
Recruiting |
NCT06236594 -
Application of Multimodal Endoscopic Functional Imaging Technology in the Diagnosis of Common Gastrointestinal Diseases
|
||
Completed |
NCT05409196 -
Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults
|
Phase 1 | |
Enrolling by invitation |
NCT04719117 -
Retrograde Cholangiopancreatography AI Assisted System Validation on Effectiveness and Safety
|
||
Recruiting |
NCT03719209 -
Using Virtual Reality for Patients With Gastrointestinal Disease
|
N/A | |
Enrolling by invitation |
NCT03319446 -
Collection of Anonymized Samples
|
N/A | |
Enrolling by invitation |
NCT03234543 -
Remote Ischemic Conditioning in Abdominal Surgery
|
N/A | |
Completed |
NCT04498208 -
Immune Modulation by Enhanced vs Standard Prehabilitation Program Before Major Surgery
|
N/A | |
Completed |
NCT03549494 -
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
|
Phase 2 | |
Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
Completed |
NCT03723447 -
Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
|
Phase 4 | |
Not yet recruiting |
NCT04514042 -
Comparison of Zenker's Diverticulum Treatment Using Peroral Endoscopic Myotomy and Flexible Endoscopy Septotomy.
|
N/A | |
Suspended |
NCT04519086 -
The Optimization of a Low-dose CT Protocol in Patients With Suspected Uncomplicated Acute Appendicitis and BMI >30
|
N/A | |
Completed |
NCT03019042 -
Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Non-organic Gastrointestinal Disorders
|
N/A | |
Completed |
NCT05008640 -
Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™
|